Systemic oncological treatments in patients with advanced pancreatic cancer: A scoping review and evidence map. Supportive Care in Cancer Salazar J (1), Bracchiglione J (1,2), Acosta-Dighero R (3), Meza N (2), Meade A (1), Quintana MJ (1,6), Requeijo C (1), Rodríguez-Grijalva G (1), Santero M (1), Selva A (4, 6), Solà I (1,5,6), Bonfill X (1,5,6), Appropriateness of Systemic Oncological Treatments for Advanced Cancer (ASTAC) Research Group. (1) Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain (2) Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valparaíso, Viña del Mar, Chile (3) Department of Physical Therapy, Faculty of Medicine, University of Chile, Santiago, Chile (4) Corporació Sanitària Parc Taulí, Sabadell, Spain (5) CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain (6) Universitat Autònoma Barcelona, Barcelona, Spain. Corresponding author: Xavier Bonfill Cosp, C/ Sant Antoni Maria Claret, 167, Pavelló 18, planta 0. 08025. Barcelona, España. Teléfono: +34 93 553 78 14 Fax: +34 93 553 78 09. xbonfill@santpau.cat 1 References of additional publications of the same study Study ID Reference Additional References Bednar, F., Ocuin, L. M., Steve, J., Zenati, M.S., Winters, S., Hogg, M. E., Bahary, N., Zeh, H. J., & Zureikat, A. H. (2016) FOLFIRINOX and  (Abstract) Bednar, F., Ocuin, L. M., Steve, J., Zenati, M.S., Winters, S., Hogg, M. E., Bahary, N., Zeh, H. Bednar, gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced J., Lii, H., & Zureikat, A. H. (2016) Folfirinox and gemcitabine/nab-paclitaxel demonstrate improved 2016 unresectable pancreatic adenocarcinoma [Abstract from 2016 ASCO Annual survival in locally advanced unresectable pancreatic adenocarcinoma [Abstract from 69th Cancer Meeting]. Journal of Clinical Oncology, 34(4_suppl), 399–399. Symposium of the Society of Surgical Oncology]. Annals of Surgical Oncology, 23(1_suppl), S175–S176. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.399 Mallinson, C. N., Rake, M. O., Cocking, J. B., Fox, C. A., Cwynarski, M. T., Diffey, B. L., Jackson, G. A., Hanley, J., & Wass, V. J. (1980). Mallinson,  (Abstract) Mallinson, C. N., Rake, M.O., & Fox, C.A. (1977). Final results of a controlled trial of Chemotherapy in pancreatic cancer: results of a controlled, prospective, 1980 chemotherapy for inoperable pancreatic cancer [Abstract]. Irish Journal of Medical Science, 146(suppl.1) randomised, multicentre trial. British medical journal, 281(6255), 1589– 1591. https://doi.org/10.1136/bmj.281.6255.1589 Xinopoulos, D., Dimitroulopoulos, D., Karanikas, I., Fotopoulou, A., Oikonomou, N., Korkolis, D., Kouroumalis, E., Antsaklis, G., Vassilopoulos,  Xinopoulos, D., Dimitroulopoulos, D., Fotopoulou, A., Korkolis, D., Tsamakidis, K., Kypreos, D., Xinopoulos, P., & Paraskevas, E. (2008). Gemcitabine as palliative treatment in patients Basioukas, S., Pasavela, S., Loukou, A. & Paraskevas, E. (2009). Palliation with Previously Gemcitabine in 2008 with unresectable pancreatic cancer previously treated with placement of a Patients with Advanced Pancreatic Cancer Treated with the Placement of a Covered Metal Biliary Stent. covered metal stent. A randomized controlled trial. Journal of B.U.ON. : Annals of Gastroenetology, 22(1), 0–15. official journal of the Balkan Union of Oncology, 13(3), 341–347. Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B.,  (Trial Resgistry) Nr. ISRCTN52780546 Riess, H., & Oettle, H. (2011). Best supportive care (BSC) versus oxaliplatin,  (Abstract) Oettle, H., Pelzer, U., Stieler, J., Hilbig, A., Roll, L., Schwaner, I., Adler, M., Detken, S., Pelzer, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line Dorken, B., & Riess, H. (2005). Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care 2011 advanced pancreatic cancer: a phase III-study from the German CONKO- versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced study group. European journal of cancer (Oxford, England : 1990), 47(11), pancreatic cancer (CONKO 003) [Abstract from 2005 ASCO Annual Meeting]. Journal of Clinical 1676–1681. https://doi.org/10.1016/j.ejca.2011.04.011 Oncology, 23(16_suppl), 4031–4031. https://doi.org/10.1200/jco.2005.23.16_suppl.4031 Chin, V., Nagrial, A., Sjoquist, K., O'Connor, C. A., Chantrill, L., Biankin,  (Protocol) Nagrial, A., Chantrill, L., Chin, V., Sjoquist, K., O'Connor, C. A., & Yip, D. (2013) A. V., Scholten, R. J., & Yip, D. (2018). Chemotherapy and radiotherapy for Chin, 2018 Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer. Cochrane Database of advanced pancreatic cancer. The Cochrane database of systematic reviews, Systematic Reviews. Art. No.: CD010584. https://doi.org//10.1002/14651858.CD010584 3(3), CD011044. https://doi.org/10.1002/14651858.CD011044.pub2 Gilliam, A. D., Broome, P., Topuzov, E. G., Garin, A. M., Pulay, I.,  (Abstract) Gilliam, A. D., Topuzov, E. G., Garin, A. M., Pulay, I., Broome, P., Watson, S. A., Rowlands, Humphreys, J., Whitehead, A., Takhar, A., Rowlands, B. J., & Beckingham, B. J., Takhar, A., & Beckingham, I. J. (2004). Randomised, double blind, placebo-controlled, multi-centre, Gilliam, I. J. (2012). An international multicenter randomized controlled trial of group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take 2012 G17DT in patients with pancreatic cancer. Pancreas, 41(3), 374–379. chemotherapy [Abstract from 2004 ASCO Annual Meeting]. Journal of Clinical Oncology, 22(14_suppl), https://doi.org/10.1097/MPA.0b013e31822ade7e 2511–2511. https://doi.org/10.1200/jco.2004.22.90140.2511 Reni, M., Cereda, S., Milella, M., Novarino, A., Passardi, A., Mambrini, A.,  (Abstract) Reni, M., Cereda, S., Milella, M., Novarino, A., Passardi, A., Mambrini, A., Di Lucca, G., Di Lucca, G., Aprile, G., Belli, C., Danova, M., Bergamo, F., Franceschi, E., Ferrari, L., Belli, C., Danova, M., Bergamo, F., Franceschi, E., Rovati, B., Fugazza, C., Ceraulo, D., & Fugazza, C., Ceraulo, D., & Villa, E. (2013). Maintenance sunitinib or Villa, E. (2012). Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma Reni, 2013 observation in metastatic pancreatic adenocarcinoma: a phase II randomised (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603) [Abstract from trial. European journal of cancer (Oxford, England : 1990), 49(17), 3609– 2012 ASCO Annual Meeting]. Journal of Clinical Oncology, 30(15_suppl), 4017–4017. 3615. https://doi.org/10.1016/j.ejca.2013.06.041 https://doi.org/10.1200/jco.2012.30.15_suppl.4017 Propper, D., Davidenko, I., Bridgewater, J., Kupcinskas, L., Fittipaldo, A., Hillenbach, C., Klughammer, B., & Ducreux, M. (2014). Phase II,  (Abstract) Ducreux, M., Davidenko, I., Bridgewater, J., Kupcinskas, L., Johannsdottir, H., Van Der Horst, Propper, randomized, biomarker identification trial (MARK) for erlotinib in patients T., Klughammer, B., & Propper, D. (2011). Invstigatins potential biomarkers for survival with erlotinib in 2014 with advanced pancreatic carcinoma. Annals of oncology : official journal of patients with advanced pancreatic cancer - Results of the phase II BO21129 study [Abstract]. European the European Society for Medical Oncology, 25(7), 1384–1390. Journal of Cancer, 47 (1_suppl), S464–S464 https://doi.org/10.1093/annonc/mdu176 2  (Abstract) Hochhauser, D., Kindler, H., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Arnold, D., Oh, D. -Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E. M., McGuinness, D., Cui, K., Schlienger, K., Locker, G., & Golan, T. (2020). Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial [Abstract]. Annals of Oncology, 31(4_suppl), S940– S941. https://doi.org/10.1016/j.annonc.2020.08.2010  (Abstract) Hall, M. J., Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Park, J. O., Hochhauser, D., Arnold, D., Oh, D. -Y., Reinacher-Schick, A. C., Tortora, G., Algül, H., O'Reilly, E. M., McGuinness, D., Cui, K., Joo, S., Yoo, H.K., Patel, N., & Kindler, H. L. (2020). Pancreatic cancer (PaC)- specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial [Abstract from 2020 Gastrointestinal Cancers Symposium]. Journal of Clinical Ongology, 38(4_suppl), 648–648. https://doi.org/10.1200/JCO.2020.38.4_suppl.648  (Abstract) Schwartz, L. H., Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M.J., Oh Park, J., Hochhauser, D., Arnold, D., Oh, D. -Y., Reinacher-Schick, A., Tortora, G., Alguel, H., O'Reilly, E. M., Fromageau, J., Ghiorghiu, D. C., McGuinness, D., Locker, G. Y., & Golan, T. (2020). POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC) [Abstract from 2020 ASCO Annual Meeting]. Journal of Clinical Oncology, Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., 38(15_suppl). https://doi.org/10.1200/JCO.2020.38.15_suppl.e16800 Park, J. O., Hochhauser, D., Arnold, D., Oh, D. Y., Reinacher-Schick, A.,  (Abstract) Yoo, H. K., Kindler, H. L., McCutcheon, S., McGuinness, D., Patel, N., Hettle, R., Goodbody, Tortora, G., Algül, H., O'Reilly, E. M., McGuinness, D., Cui, K. Y., R., Joo, S., Locker, G. Y., & Golan, T. (2020). POLO: Quality-adjusted (QA) progression-free survival Golan, Schlienger, K., Locker, G. Y., & Kindler, H. L. (2019). Maintenance (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer 2019 Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. The (mPaC) [Abstract from 2020 ASCO Annual Meeting]. Journal of Clinical Oncology, 38(15_suppl), 4626– New England journal of medicine, 381(4), 317–327. 4626. https://doi.org/10.1200/JCO.2020.38.15_suppl.4626 https://doi.org/10.1056/NEJMoa1903387  (Abstract) Hammel, P., Kindler, H. L., Reni, M., Van Cutsem, E., Macarulla Mercade, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D. -Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E. M., McGuinness, D., Cui, K. Y., Joo, S., Yoo, H. K., Patel, N., & Golan, T. (2019). POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC) [Abstract]. Annals of Oncology, 30(5_suppl), V254–V255. https://doi.org/10.1093/annonc/mdz422.004  Hammel, P., Kindler, H. L., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D. Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E. M., McGuinness, D., Cui, K. Y., Joo, S., Yoo, H. K., Patel, N., Golan, T., … POLO Investigators (2019). Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Annals of oncology : official journal of the European Society for Medical Oncology, 30(12), 1959–1968. https://doi.org/10.1093/annonc/mdz406 - Golan,  T., Kindler, H. L., Park, J. O., Reni, M., Macarulla, T., Hammel, P., Van Cutsem, E., Arnold, D., Hochhauser, D., McGuinness, D., Locker, G. Y., Goranova, T., Schatz, P., Liu, Y. Z., & Hall, M. J. (2020). Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(13), 1442–1454. https://doi.org/10.1200/JCO.19.01890 3